Amgen Aktie 907582 / US0311621009
294.40
USD
4.52
USD
1.56%
22.11.2024
BTT
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Amgen Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2023 | Amgen Inc. | 2.96 | 8.52 | USD |
| 2022 | Amgen Inc. | 2.95 | 7.76 | USD |
| 2021 | Amgen Inc. | 3.13 | 7.04 | USD |
| 2020 | Amgen Inc. | 2.78 | 6.40 | USD |
| 2019 | Amgen Inc. | 2.41 | 5.80 | USD |
| 2018 | Amgen Inc. | 2.71 | 5.28 | USD |
| 2017 | Amgen Inc. | 2.65 | 4.60 | USD |
| 2016 | Amgen Inc. | 2.74 | 4.00 | USD |
| 2015 | Amgen Inc. | 1.95 | 3.16 | USD |
| 2014 | Amgen Inc. | 1.53 | 2.44 | USD |
Gewinn je Aktie- Amgen
| 2.7 17 | 12.6 18 | 12.9 19 | 12.3 20 | 10.3 21 | 12.1 22 | 12.5 23 |
Umsatz je Aktie- Amgen
| 31.0 17 | 35.7 18 | 38.2 19 | 42.8 20 | 45.4 21 | 48.2 22 | 52.1 23 |
KGV- Amgen
| 64.6 17 | 15.4 18 | 18.7 19 | 18.7 20 | 21.9 21 | 21.7 22 | 23.1 23 |
Amgen Inc.: Die Aktie (in USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie berichtet | 2.69 | 12.62 | 12.88 | 12.31 | 10.28 | 12.11 | 12.49 |
| Gewinn je Aktie unverwässert | 2.71 | 12.70 | 12.96 | 12.40 | 10.34 | 12.18 | 12.56 |
| Gewinn je Aktie verwässert | 2.69 | 12.62 | 12.88 | 12.31 | 10.28 | 12.11 | 12.49 |
| Dividende pro Aktie | 4.60 | 5.28 | 5.80 | 6.40 | 7.04 | 7.76 | 8.52 |
| Gesamtdividendenausschüttung in Mio. | 3’365.00 | 3’507.00 | 3’509.00 | 3’755.00 | 4’013.00 | 4’196.00 | 4’556.00 |
Amgen Inc.: Unternehmenskennzahlen (in USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Umsatz je Aktie | 31.00 | 35.74 | 38.20 | 42.79 | 45.35 | 48.23 | 52.06 |
| KGV (Jahresendkurs, EPS unverwässert) | 64.59 | 15.42 | 18.72 | 18.67 | 21.87 | 21.69 | 23.07 |
| KGV (Jahresendkurs, EPS verwässert) | 64.59 | 15.42 | 18.72 | 18.67 | 21.87 | 21.69 | 23.07 |
| KGV (Jahresendkurs) | 64.59 | 15.42 | 18.72 | 18.67 | 21.87 | 21.69 | 23.07 |
| Dividendenrendite Jahresende in % | 2.65 | 2.71 | 2.41 | 2.78 | 3.13 | 2.95 | 2.96 |
| Eigenkapitalquote in % | 31.57 | 18.82 | 16.20 | 14.95 | 10.95 | 5.62 | 6.41 |
| Fremdkapitalquote in % | 68.43 | 81.18 | 83.80 | 85.05 | 89.05 | 94.38 | 93.59 |
Amgen Inc.: GuV (in Mio. USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 22’784.00 | 23’768.00 | 23’261.00 | 25’246.00 | 25’987.00 | 26’092.00 | 28’010.00 |
| Umsatzveränderung in % | 0.45 | 4.32 | -2.13 | 8.53 | 2.94 | 0.40 | 7.35 |
| Bruttoergebnis vom Umsatz | 18’715.00 | 19’667.00 | 18’905.00 | 19’087.00 | 19’533.00 | 19’686.00 | 19’595.00 |
| Bruttoergebnisveränderung in % | 1.05 | 5.09 | -3.87 | 0.96 | 2.34 | 0.78 | -0.46 |
| Operatives Ergebnis | 10’018.00 | 10’326.00 | 9’573.00 | 8’961.00 | 9’152.00 | 9’335.00 | 8’471.00 |
| Veränderung Operatives Ergebnis in % | 5.19 | 3.07 | -7.29 | -6.39 | 2.13 | 2.00 | -9.26 |
| Ergebnis vor Steuern | 9’597.00 | 9’545.00 | 9’138.00 | 8’133.00 | 6’701.00 | 7’346.00 | 7’855.00 |
| Veränderung Ergebnis vor Steuern in % | 4.74 | -0.54 | -4.26 | -11.00 | -17.61 | 9.63 | 6.93 |
| Ergebnis nach Steuer | 1’979.00 | 8’394.00 | 7’842.00 | 7’264.00 | 5’893.00 | 6’552.00 | 6’717.00 |
| Veränderung Ergebnis nach Steuer in % | -74.37 | 324.15 | -6.58 | -7.37 | -18.87 | 11.18 | 2.52 |
Amgen Inc.: Bilanz (in Mio. USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Gesamtverbindlichkeiten | 54’713 | 53’916 | 50’034 | 53’539 | 54’465 | 61’460 | 90’922 |
| Langzeit Gesamtverbindlichk. pro Aktie | 63.27 | 64.21 | 62.90 | 72.43 | 75.73 | 85.72 | 135.47 |
| Eigenkapital | 25’241 | 12’500 | 9’673 | 9’409 | 6’700 | 3’661 | 6’232 |
| Veränderung Eigenkapital in % | -15.51 | -50.48 | -22.62 | -2.73 | -28.79 | -45.36 | 70.23 |
| Bilanzsumme | 79’954 | 66’416 | 59’707 | 62’948 | 61’165 | 65’121 | 97’154 |
| Veränderung Bilanzsumme in % | 3.00 | -16.93 | -10.10 | 5.43 | -2.83 | 6.47 | 49.19 |
Amgen Inc.: Sonstige Angaben (in USD)
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | 2.71 | 12.70 | 12.96 | 12.40 | 10.34 | 12.18 | 12.56 |
| Veränderung Gewinn je Aktie (unverwässert) in % | -73.78 | 369.08 | 2.07 | -4.37 | -16.60 | 17.80 | 3.09 |
| Gewinn je Aktie (verwässert) | 2.69 | 12.62 | 12.88 | 12.31 | 10.28 | 12.11 | 12.49 |
| Veränderung Gewinn je Aktie (verwässert) in % | -73.71 | 368.81 | 2.01 | -4.39 | -16.47 | 17.76 | 3.09 |
| Anzahl Mitarbeiter | 20’800 | 21’500 | 23’400 | 24’300 | 24’200 | 25’200 | 26’700 |
| Veränderung Anzahl Mitarbeiter in % | 8.33 | 3.37 | 8.84 | 3.85 | -0.41 | 4.13 | 5.95 |
Amgen Inc. Termine
| Unternehmen | Event | Datum |
|---|---|---|
| Amgen Inc. | Quartalszahlen | 04.02.2025 |
| Amgen Inc. | Quartalszahlen | 01.05.2025 |
| Amgen Inc. | Quartalszahlen | 05.08.2025 |
| Amgen Inc. | Quartalszahlen | 04.11.2025 |
Amgen Inc. vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Quartalszahlen | Q3 2024 Earnings Release | 30.10.2024 |
| Quartalszahlen | Q2 2024 Earnings Release | 06.08.2024 |
| Hauptversammlung | Annual General Meeting | 31.05.2024 |
| Quartalszahlen | Q1 2024 Earnings Release | 02.05.2024 |
| Quartalszahlen | Q4 2023 Earnings Release | 06.02.2024 |
| Quartalszahlen | Q3 2023 Earnings Release | 31.10.2023 |
| Quartalszahlen | Q2 2023 Earnings Release | 03.08.2023 |
| Hauptversammlung | Annual General Meeting | 19.05.2023 |
| Quartalszahlen | Q1 2023 Earnings Release | 27.04.2023 |
| Quartalszahlen | Q4 2022 Earnings Release | 31.01.2023 |
| Quartalszahlen | Q3 2022 Earnings Release | 03.11.2022 |
| Quartalszahlen | Q2 2022 Earnings Release | 04.08.2022 |
| Hauptversammlung | Annual General Meeting | 17.05.2022 |
| Quartalszahlen | Q1 2022 Earnings Release | 27.04.2022 |
| Quartalszahlen | Q4 2021 Earnings Release | 07.02.2022 |
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 99.74 |
| Vanguard Group, Inc. (Subfiler) | 9.28 |
| The Vanguard Group, Inc. | 9.13 |
| SSgA Funds Management, Inc. | 5.50 |
| State Street Corp. | 5.46 |
| Vanguard Total Stock Market ETF | 3.16 |
| BlackRock Fund Advisors | 3.07 |
| PRIMECAP Management Co. | 2.65 |
| Vanguard 500 Index Fund | 2.65 |
| Geode Capital Management LLC | 2.26 |
| BlackRock Institutional Trust Co. NA | 2.21 |
| Charles Schwab Investment Management, Inc. | 1.96 |
| Invesco QQQ Trust | 1.94 |
| Vanguard PRIMECAP Fund | 1.67 |
| Capital Research & Management Co. (International Investors) | 1.62 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 23’400 | 24’300 | 24’200 | 25’200 | 26’700 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.99 | 1.04 | 1.07 | 1.04 | 1.05 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 18’440 | 21’144 | 19’385 | 22’186 | 30’332 |
| Summe Anlagevermögen | 41’267 | 41’804 | 41’780 | 42’935 | 66’822 |
| Summe Aktiva | 59’707 | 62’948 | 61’165 | 65’121 | 97’154 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 30’431 | 33’445 | 33’979 | 39’640 | 65’423 |
| Summe Fremdkapital | 50’034 | 53’539 | 54’465 | 61’460 | 90’922 |
| Summe Eigenkapital | 9’673 | 9’409 | 6’700 | 3’661 | 6’232 |
| Summe Passiva | 59’707 | 62’948 | 61’165 | 65’121 | 97’154 |
Adresse
| One Amgen Center Drive, 91320-1799 Thousand Oaks | |
| Telefon | +1 (805) 447-1000 |
| Fax | +1 (805) 447-1010 |
| URL | http://www.amgen.com |
Management
|
Amy E. Miles
Independent Director |
|
Brian J. Druker
Independent Director |
|
Charles M. Holley
Independent Director |
|
Darryl Sleep
Chief Medical Officer & Senior VP-Global Medical |
|
David M. Reese
Chief Technology Officer & Executive VP |
|
Derek Miller
Chief Human Resources Officer |
|
Ellen Jamison Kullman
Independent Director |
|
Esteban Santos
Executive Vice President-Operations |
|
Greg C. Garland
Independent Director |
|
James E. Bradner
Chief Scientific Officer |
|
Jean-Charles Soria
SVP-Research and Development |
|
Jonathan P. Graham
Secretary, Executive VP & General Counsel |
|
Li Yang
Scientific Director |
|
Linda H. Louie
Chief Accounting Officer & Vice President-Finance |
|
Linda H. Louie
Vice President-Finance |
|
Lori A. Johnston
Executive Vice President |
|
Mark J. Taisey
Senior VP-Global Regulatory Affairs & Strategy |
|
Mary Earley Klotman
Director |
|
Matthew C. Busch
Chief Accounting Officer & Vice President-Finance |
|
Michael V. Drake
Independent Director |
|
Mike Zahigian
Chief Information Officer & Senior Vice President |
|
Murdo J. Gordon
EVP-Global Commercial Operations |
|
Nancy A. Grygiel
Chief Compliance Officer |
|
Omar Syed Ishrak
Independent Director |
|
Paul Burton
Chief Medical Officer |
|
Peter H. Griffith
Chief Financial Officer & Executive Vice President |
|
Rachna Khosla
Senior Vice President-Business Development |
|
Robert A. Bradway
Chairman, President & Chief Executive Officer |
|
Robert A. Eckert
Lead Independent Director |
|
Robert T. Fremeau
Scientific Director |
|
Susan Sweeney
Senior VP-Global Marketing, Access & Capabilities |
|
Tyler E. Jacks
Independent Director |
|
Victoria H. Blatter
Senior Vice President-Global Government Affairs |
|
Wanda M. Austin
Independent Director |